Heart1.com: Great Information, Real Community, Better Living.
 Main Page
 Heart News
Feature Story
 Education Center
 Heart Attack Center
Dr. Tod Engelhardt  Heart

Dr. Tod Engelhardt:
Combating Major Blood Clots.
About Heroes
 Join the Discussion  in  Our Forums
Heart1 Forums
Patient Stories
Online Resources
Video Library
Search the Body1 Network
May 22, 2019  
HEART NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • Boston Scientific Presents Stent Trials Results

    Boston Scientific Presents Results from TAXUS Stent Trials at TCT

    October 15, 2003
    By Stephanie Riesenman for Heart1

    Boston Scientific is awaiting approval by the Food and Drug Administration of its new drug-eluting stent, called TAXUS, now that results from a new study on patients with coronary artery disease have shown that it significantly reduces the need for repeat angioplasty or coronary artery bypass surgery within a year.

    "Restenosis remains the Achilles heel of percutaneous (performed through the skin) coronary angioplasty," said Dr. Greg Stone, Director of the Cardiovascular Research Institute and the Lenox Hill Heart and Vascular Institute. He presented the findings of the TAXUS trial at the 2003 Transcatheter Cardiovascular Therapeutics meeting in September.

    Doctors place metal stents in the coronary arteries to provide a scaffolding to keep the vessel open after it has been cleared of artery clogging plaque. In about 25 percent of patients, smooth muscle cells grow and clog up the stent within six months, almost like a scar forming over an injury, necessitating a repeat procedure. This is called restenosis.

    To solve the problem of restenosis, companies like Boston Scientific have begun covering their stents with drugs that interrupt the biological processes that cause restenosis. The first company to receive FDA approval for their drug-eluting stent was Johnson and Johnson’s Cordis. It received approval to sell CYPHER in the United States last April.

    The TAXUS stent elutes a drug called paclitaxel into the artery over several weeks. Its efficacy was tested in a trial of more than 1,300 patients with coronary artery disease, whose average age was 62 years. The TAXUS drug-eluting stent was placed in half of the patients in the trial, while the other half received an identical looking stent that did not have a drug coating. Neither the patients nor their doctors were aware of which stent was being placed.

    Patients were assessed at one, four, and nine months, and they will continue to be followed for five years. TAXUS reduced the need for repeat angioplasty or bypass surgery due to restenosis by 73 percent versus the traditional stent at nine months. It also reduced the need for additional catheterizations in the same vessel by 61 percent.

    In another way of looking at the data, Dr. Stone said that 96 percent of patients with the TAXUS stent did not have a restenosis at nine months, compared to 87.5 percent of patients in the standard stent group.

    The TAXUS stent was particularly effective in diabetic patients, and the company hopes the study results will give it an advantage over Johnson and Johnson’s CYPHER. Diabetics are considered high risk for coronary artery disease. When the researchers looked specifically at these patients, TAXUS was shown to prevent restenosis in 70 percent of the study participants.

    In wrapping up the presentation, Dr. Stone concluded that TAXUS, "is effective in a wide range of complex patients and lesions, including small vessels, long lesions, and patients with diabetes."

    Boston Scientific is anticipating approval of its new stent later this year or early 2004. TAXUS has been sold in Europe and other international markets since February.

    Last updated: 15-Oct-03


  • Add Comment
    Interact on Heart1

    Discuss this topic with others.
    Feature Archives

    Heart Disease Patients Need to Exercise to Benefit from the Protective Effects of Wine

    Effective Treatment for Heart Failure Possible Following Discovery of Heart Molecule

    Significant Decrease in Heart Disease after Prison Smoking Bans

    Heart Failure Patients Who Sleep Poorly Are at Double the Risk for Hospitalization

    Long-Term Survival Possible for Pediatric Heart Transplant Patients

    Next 5 Features ...

    More Features ...
    Related Multimedia

    Interview with Dr. Chen - Gerd and Gastroenterology

    Interview with Dr. Foley: Heartburn and GERD

    Coronary Angioplasty

    More Features ...
    Related Content
    Boston Scientific Anticipates Taxus Stent Launch

    Boston Scientific Stent Is Approved

    Heart Stories: Victory Over Heart Disease

    J&J, Guidant to Co-Promote Heart Stents

    Drug-Coated Stents Aid Angioplasties

    More Features ...
    Home About Us Press Jobs Advertise With Us Contact Us
    © 2019 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.